Study wrapper · #1279
Cardiorenal Mortality and Safety Outcomes of GLP-1 Receptor Agonists in Type 2 Diabetes With BMI Below 27 kg/m2: A Target Trial Emulation.
Editor's note
The exposure is the GLP-1 receptor agonist class excluding tirzepatide, so this is class-level evidence rather than a semaglutide-specific result. The authors are candid that the mortality gap versus DPP-4 inhibitors is implausibly large and likely reflects residual confounding, and its disappearance against SGLT2 inhibitors, an active comparator with its own survival benefit, supports that reading. The consistently lower coded heart-failure risk across all three comparisons is the finding most likely to survive scrutiny. Observational design, 24-month maximum follow-up, coded outcomes only.
Plain-language abstract
Using US electronic health records, investigators emulated a randomised trial in adults with type 2 diabetes and a BMI below 27, a group largely absent from the big GLP-1 outcome trials. Against DPP-4 inhibitors, people starting a GLP-1 receptor agonist had lower all-cause mortality, fewer major cardiovascular events and less coded heart failure; against SGLT2 inhibitors the cardiovascular and heart-failure differences held but the mortality difference did not. Gastroparesis was recorded more often in the GLP-1 group.